FCF belongs to the family of diarylureas, a large group containing pharmacologically active compounds, some of which function as serine-threonine kinase or tyrosine kinase inhibitors, and some are used as anti-cancer drugs, e.g., sorafenib and regorafenib; for details, see [29]. The gene discussed is MARK2; the disease is cancer.